Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 9/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15731128 | 0.92 | APP (0.52) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL22006732 | 0.92 | APP (0.52) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL3335259 | 0.88 | FAAH (0.62) | FAAH | |
| SCHEMBL13637520 | 0.88 | FAAH (0.62) | ALDH1A1FAAH | |
| SCHEMBL13827423 | 0.87 | CYP17A1 (0.48) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL22568331 | 0.87 | LMNA (0.51) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL29730607 | 0.87 | CYP17A1 (0.48) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL23142821 | 0.85 | TP53 (0.51) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL13306489 | 0.85 | CA1 (0.66) | CYP17A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL1422634 | 0.85 | FAAH (0.49) | CYP17A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| WO-2019202884-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, LIQUID CRYSTAL ELEMENT, POLYMER, AND COMPOUND | JSR株式会社 | 2019-10-24 | — | — | WO | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8765920-B2 | Tyrosine bioconjugation through aqueous Ene-like reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2376085-B1 | COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2376085-A1 | COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080478-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-0912182-A4 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO INC (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5990107-A | ADMINISTERING TO INHIBIT THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS IN A MAMMAL; OR TO INHIBIT OSTEOCLAST MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0912182-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998000144-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HDAC1, HDAC6, HDAC3 | CYP17A1 2649/4885ALDH1A1 1861/4885CA12 3306/4885 |
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | CYP17A1 1113/4885ALDH1A1 3814/4885CA12 2017/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | CYP17A1 1113/4885ALDH1A1 3814/4885CA12 2017/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | CYP17A1 1113/4885ALDH1A1 3814/4885CA12 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.